Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

margetuximab-cmkb

View Patient Information
A Fc-domain optimized IgG monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2) with potential immunomodulating and antineoplastic activities. After binding to HER2 on the tumor cell surface, margetuximab may induce an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells overexpressing HER2. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types. Compared to other anti-HER2 monoclonal antibodies, the Fc domain of MGAH22 is optimized with increased binding to the activating Fcgamma receptor IIIA (CD16A), expressed on cells such as natural killer (NK) cells and macrophages, thereby mediating an enhanced ADCC; the Fc domain also shows decreased binding to the inhibitory Fcgamma receptor IIB (CD32B).
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:margetuximab
US brand name:Margenza
Code name:MGAH22
Chemical structure:immunoglobulin G1, anti-(human Neu (receptor)) (human-Mus musculus monoclonal MGAH22 Clone ch4D5 heavy dhain), disulfide with human-Mus musculus monoclonal MGAH22 clone ch4D5 light chain, dimer
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search